{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:09Z","timestamp":1786119429856,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8,24]]},"DOI":"10.1097\/qad.0b013e32832d3b54","type":"journal-article","created":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T15:49:22Z","timestamp":1250178562000},"page":"1689-1699","source":"Crossref","is-referenced-by-count":60,"title":["Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy"],"prefix":"10.1097","volume":"23","author":[{"given":"Anouk M","family":"Kesselring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand W","family":"Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A","family":"Sabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens D","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M John","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andri","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio S","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"de Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mocroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.279.12.930","article-title":"A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study","volume":"279","author":"Montaner","year":"1998","journal-title":"JAMA"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00002030-199606000-00009","article-title":"A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group","volume":"10","author":"Carr","year":"1996","journal-title":"AIDS"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.7326\/0003-4819-124-12-199606150-00001","article-title":"Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators","volume":"124","author":"D'Aquila","year":"1996","journal-title":"Ann Intern Med"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1086\/514002","article-title":"High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication","volume":"175","author":"de","year":"1997","journal-title":"J Infect Dis"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1086\/520242","article-title":"Severe hepatic failure related to nevirapine treatment","volume":"29","author":"Cattelan","year":"1999","journal-title":"Clin Infect Dis"},{"key":"R7-8-20210130","first-page":"1115","article-title":"Nevirapine-induced hepatitis treated with corticosteroids?","volume":"12","author":"Leitze","year":"1998","journal-title":"AIDS"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(98)24008-6","article-title":"Nevirapine-associated Stevens-Johnson syndrome","volume":"351","author":"Warren","year":"1998","journal-title":"Lancet"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(99)91384-3","article-title":"HIV-1 infected patients with toxic epidermal necrolysis: an occupational risk for healthcare workers","volume":"353","author":"Descamps","year":"1999","journal-title":"Lancet"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(05)79417-4","article-title":"Nevirapine and rashes","volume":"351","author":"Barner","year":"1998","journal-title":"Lancet"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-200501280-00011","article-title":"Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs","volume":"19","author":"Ananworanich","year":"2005","journal-title":"AIDS"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/00126334-200404150-00014","article-title":"Hepatotoxicity associated with nevirapine use","volume":"35","author":"Baylor","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/135965350701200305","article-title":"Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts","volume":"12","author":"Mocroft","year":"2007","journal-title":"Antivir Ther"},{"key":"R15-8-20210130","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1086\/528861","article-title":"Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study","volume":"46","author":"Wit","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/QAI.0b013e31804d685b","article-title":"CD4 cell counts of 800 cells\/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells\/mm3 or greater","volume":"45","author":"Gras","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(98)03201-2","article-title":"Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group","volume":"352","author":"Mocroft","year":"1998","journal-title":"Lancet"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1468-1293.2005.00271.x","article-title":"Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003","volume":"6","author":"Krentz","year":"2005","journal-title":"HIV Med"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1468-1293.2004.00197.x","article-title":"The UK Collaborative HIV Cohort (UK CHIC) Study.","volume":"5","year":"2004","journal-title":"HIV Med"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1097\/QAD.0b013e3282170a9d","article-title":"Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients","volume":"21","author":"Phillips","year":"2007","journal-title":"AIDS"},{"key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0140-6736(99)01122-8","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study","volume":"353","author":"Ledergerber","year":"1999","journal-title":"Lancet"},{"key":"R23-8-20210130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1468-1293.2008.00552.x","article-title":"Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts","volume":"9","author":"De Lazzari","year":"2008","journal-title":"HIV Med"},{"key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/00002030-200005050-00006","article-title":"Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy","volume":"14","author":"Barreiro","year":"2000","journal-title":"AIDS"},{"key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/340131","article-title":"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression","volume":"185","author":"Dieleman","year":"2002","journal-title":"J Infect Dis"},{"key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"R27-8-20210130","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","article-title":"HLA-Cw8 primarily associated with hypersensitivity to nevirapine","volume":"21","author":"Gatanaga","year":"2007","journal-title":"AIDS"},{"key":"R28-8-20210130","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/01.aids.0000238408.82947.09","article-title":"HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients","volume":"20","author":"Littera","year":"2006","journal-title":"AIDS"},{"key":"R29-8-20210130","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/tx0501132","article-title":"Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat","volume":"18","author":"Shenton","year":"2005","journal-title":"Chem Res Toxicol"},{"key":"R30-8-20210130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00130832-200108000-00006","article-title":"HIV and drug allergy","volume":"1","author":"Pirmohamed","year":"2001","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R31-8-20210130","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/135965350801300814","article-title":"Refining abacavir hypersensitivity diagnosis using a structural clinical assessment and genetic testing in the Swiss HIV Cohort Study","volume":"13","author":"Rauch","year":"2008","journal-title":"Antivir Ther"},{"key":"R32-8-20210130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1086\/317536","article-title":"Sex differences in nevirapine rash","volume":"32","author":"Bersoff-Matcha","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R33-8-20210130","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/00002030-200108170-00018","article-title":"Female sex and the use of antiallergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy","volume":"15","author":"Antinori","year":"2001","journal-title":"AIDS"},{"key":"R34-8-20210130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.aids.0000162334.12815.5b","article-title":"The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART","volume":"19","author":"van","year":"2005","journal-title":"AIDS"},{"key":"R35-8-20210130","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1097\/00002030-199815000-00026","article-title":"High incidence of nevirapine-associated rash in HIV-infected Chinese","volume":"12","author":"Ho","year":"1998","journal-title":"AIDS"},{"key":"R36-8-20210130","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects","volume":"191","author":"Sanne","year":"2005","journal-title":"J Infect Dis"},{"key":"R37-8-20210130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","article-title":"Are adverse events of nevirapine and efavirenz related to plasma concentrations?","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir Ther"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200908240-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:12Z","timestamp":1786039692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200908240-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,24]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32832d3b54","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8,24]]}}}